This article takes a closer look at AI and intelligent technologies and what we can expect to tackle in 2022 and beyond.

With current use cases across three categories: people, technology, and business, we discuss how AI and intelligent technologies are being used in the Life Sciences, identify some of the new concerns and challenges with disruptive technologies and risk management, and review a technology and generation timeline.

AI and intelligent technologies are not to be feared and avoided; rather, they should be embraced and included in the disruptive technologies and internet of things (IoT) strategy and framework.

You can read the full article here.

About The Author:

Kathleen-WarnerKathleen Warner, Ph.D., VP of Consulting Services for RCM Technologies, Life Sciences, is an executive consultant with 25+ years of experience in information technology (IT) and the life sciences. She has served as a chief information officer, subject matter expert, and domain expert in regulated environments. As a management consultant, Warner has provided oversight for hundreds of life science projects both in the U.S. and globally. Her strengths include leadership, advisory, organization change management, business process analyses, and program/project management engagements. As a practitioner and technologist, Warner has performed future cloud assessments to define the IT infrastructure roadmap, clinical sample management process analyses, R&D IT program management, and more.